INSIDE THIS ISSUE:

Feline Diabetes 2
Canine Acral Lick Dermatitis 3
Canine Aspirin Induced Gastric Injury 4

PRESCRIPTION COMPOUNDING FOR

VETERINARY MEDICINE

757 Norland Avenue, Suite 105
Chambersburg, PA 17201
Phone: (717) 217-6790
Fax: (717) 217-6925
Web: www.NorlandAvenuePharmacy.com
**FELINE DIABETES**

The following study suggests that glipizide is feasible in diabetic cats of owners who are unable or unwilling to administer insulin - “Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus” (J Am Vet Med Assoc. 1997 Mar 15;210(6):772-7).

**OBJECTIVE:** To evaluate use of the oral hypoglycemic drug glipizide in diabetic cats. DESIGN: Prospective study.

**ANIMALS:** 50 cats with recently diagnosed but untreated diabetes mellitus.

**PROCEDURE:** Each cat received glipizide (5 mg, q 12 h) for 16 weeks. Medication was not given during the subsequent 16 weeks; then glipizide treatment was repeated. Each cat was evaluated prior to treatment and at 2, 4, 8, 12, and 16 weeks during each of the 3 phases: blood samples for serum glucose and insulin determinations were obtained every 2 hours, from 8 AM to 6 PM. A preprandial blood glycosylated hemoglobin percentage was determined for the first sample obtained at each visit.

**RESULTS:** During the first 22 weeks of the study, diabetes worsened in 28 of the 50 cats, which then were disqualified from the study and treated with insulin. Of the remaining 22 cats that improved clinically, 7 had corresponding metabolic improvement in each diabetes-related parameter assessed and did not become hypoglycemic. Six of the 22 cats became hypoglycemic. Glipizide was discontinued, and diabetes did not recur. Serum glucose concentration did not improve in 6. Three cats had metabolic and clinical improvement during initial glipizide treatment, but had recurrence of the disease during repeated treatment; glipizide was discontinued and insulin was administered. None of the 50 treated cats died, and observed morbidity was mild and transient. Transient anorexia and vomiting were observed in 8 cats, and 4 became transiently icteric with abnormal liver enzyme activities.

**CLINICAL IMPLICATIONS:** Trial use of glipizide is feasible in diabetic cats of owners who are unable or unwilling to administer insulin. PMID: 9074678

With our state of the art compounding lab and pharmaceutical knowledge and experience, we can compound glipizide into a flavored oral solution.

**COMPOUNDED MEDICATION**

<table>
<thead>
<tr>
<th>Glipizide 5mg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flavored Oral Solution</td>
</tr>
<tr>
<td>60ml</td>
</tr>
<tr>
<td>Give 1ml po Q12H or as directed</td>
</tr>
</tbody>
</table>

An example of how you might prescribe follows:
C A N I N E  A C R A L  L I C K  D E R M A T I T I S

The following clinical paper found successful treatment in 7 of 11 dogs treated with naltrexone for acral lick dermatitis - “Naltrexone for treatment of acral lick dermatitis in dogs (J Am Vet Med Assoc. 1990 Apr 1;196(7):1073-6).

ABSTRACT: “Acral lick dermatitis (lick granuloma) was diagnosed in 11 dogs on the basis of history, physical examination, and histopathologic findings. A predilection for the left forelimb was noticed. All 11 dogs were given the narcotic antagonist naltrexone. Successful treatment (cessation of licking, reepithelialization of lesions) was seen in 7 dogs. All 7 dogs’ lesions recurred when naltrexone was stopped, but reepithelialized in 5 dogs when the drug was readministered. Adverse effects (drowsiness, withdrawal from owner) were seen in 1 dog, but resolved within 48 hours of stopping the drug.” PMID: 2329076

With our state of the art compounding laboratory and pharmaceutical knowledge and experience, we have the ability to compound naltrexone into a flavored oral suspension; in a variety of strengths that meet the needs of each of your dogs.

An example of how you might prescribe follows:

<table>
<thead>
<tr>
<th>COMPOUNDED MEDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naltrexone 1mg/ml</td>
</tr>
<tr>
<td>Flavored Oral Suspension</td>
</tr>
<tr>
<td>30ml</td>
</tr>
<tr>
<td>Give 1ml QD or as directed</td>
</tr>
</tbody>
</table>


ABSTRACT: “The effect of twice-daily administration of misoprostol on aspirin-induced gastric injury was evaluated. Twenty-four random-source dogs were divided into groups that received aspirin and misoprostol as follows: group I, aspirin 25 mg/kg PO q8h and placebo PO q8h; group II, aspirin 25 mg/kg PO q8h and misoprostol 3 microg/kg PO q8h; group III, aspirin 25 mg/kg PO q8h, misoprostol 3 microg/kg PO q12h, and placebo PO q24h; and group IV, aspirin 25 mg/kg PO q8h, misoprostol 3 microg/kg PO q24h, and placebo PO q12h for 28 days. Gastroscopy was performed on days -9, 5, 14, and 28. Visible lesions were scored on a scale of 1 (mucosal hemorrhage) to 11 (perforating ulcer). No difference in total score was identified between groups I and IV on any day. Median total scores for groups II and III were significantly (P < or = .05) lower compared to groups I and IV on day 5. Group III had a significantly lower score (P < or = .05) than groups I, II, and IV on day 28. This study suggests that misoprostol 3 microg/kg PO q12h is as effective as misoprostol 3 microg/kg PO q8h in preventing aspirin-induced gastric injury in this model. However, misoprostol 3 microg/kg PO q8h was less effective in preventing aspirin-induced gastric injury on days 14 and 28 than in previous studies. No difference among numbers of dog-days of vomiting, diarrhea, or anorexia was detected among groups.” PMID: 12774967

An example of how you might prescribe follows:

**COMPOUNDED MEDICATION**

<table>
<thead>
<tr>
<th>Misoprostol 10mcg/ml</th>
<th>Flavored Oral Suspension</th>
</tr>
</thead>
<tbody>
<tr>
<td>60ml</td>
<td>Give 1ml po BID or as directed</td>
</tr>
</tbody>
</table>

We have the ability to compound misoprostol into a flavored oral suspension.


ABSTRACT: “Misoprostol, a synthetic prostaglandin E1 analog, is effective in treating and preventing nonsteroidal antiinflammatory drug (NSAID)–induced gastroduodenal lesions in humans. The effectiveness of misoprostol in preventing aspirin-induced gastroduodenal injury was studied in 3 groups of 6 adult mixed breed dogs. Group I received 3 micrograms/kg misoprostol PO tid. Group II received 3 micrograms/kg misoprostol PO tid and 35 mg/kg aspirin PO tid. Group III received 35 mg/kg aspirin PO tid. Endoscopy was performed on days 0, 5, 14, and 30. Five regions of the upper gastrointestinal tract were qualitatively scored from 1 to 12 based on the presence of submucosal hemorrhage, erosion, or ulceration, with ulceration receiving a higher numerical score than submucosal hemorrhage. A total score was assigned based on the sum of the scores from all regions. Comparisons among groups on each day were performed using the Kruskal-Wallis test. Differences within a group among different time periods were determined using appropriate multiple comparisons. Significant difference in mean gastroduodenal lesion score was found among all groups at 5, 14, and 30 days. Mean total score on days 5, 14, and 30 were as follows: group I, 5.0, 5.2, 9.0; group II, 12.0, 12.7, 16.2; and group III, 26.0, 23.8, 21.5, respectively. Significant differences within a group among different time periods were found from days 0 to 5 in groups I and II, and from days 14 to 30 in group I. It was concluded that misoprostol effectively decreased endoscopically detectable mucosal lesions in dogs given aspirin.” PMID: 7891360
Feline Diabetes

- [ ] Glipizide 5mg/ml
- Flavored Oral Solution
- Quantity 60ml
- Directions: Give 1ml po Q12H or as directed

Canine Acral Lick Dermatitis

- [ ] Naltrexone 1mg/ml
- Flavored Oral Suspension
- Quantity 30ml
- Directions: Give 1ml QD or as directed

Canine Aspirin Induced Gastric Injury

- [ ] Misoprostol 10mcg/ml
- Flavored Oral Suspension
- Quantity 60ml
- Directions: Give 1ml po BID or as directed

**Directions**

_________________________________________________________________________________________________________

Prescriber’s Signature_____________________________________________________

Refills: 1 2 3 4 5 6 7 8 9 10 11 12 NR

———

Norland Avenue PHARMACY Compounding & Gifts LLC

757 Norland Avenue, Suite 105
Chambersburg, PA 17201
Phone: (717) 217-6790
Fax: (717) 217-6925